MedCom Gesellschaft für medizinische Bildverarbeitung mbH

MedCom specializes in developing radiation therapy software, focusing on tools for planning, quality assurance, and verification in radiotherapy. Their products include systems for treatment planning, dose calculation, and workflow optimization to improve precision during radiation therapy. These solutions are designed to support pre-treatment checks, dose optimization, and real-time monitoring, ensuring safer and more accurate delivery of radiation treatments.

MedCom is based in the United States, which means its devices must comply with U.S. medical device regulations, including those governing software used in radiation therapy. Since their products fall under Class I and Class II classifications, they are subject to specific regulatory requirements depending on the risk level, such as premarket notifications (510(k)) for Class II devices. The company’s location also influences which registries and databases its devices appear in, such as the FDA’s Unique Device Identifier (UDI) system.

MedCom’s devices are listed in the FDA’s Unique Device Identifier (UDI) database, which is a standardized system for tracking medical devices in the U.S. This listing is important because it ensures traceability, transparency, and compliance with regulatory requirements. Healthcare providers, inspectors, and other stakeholders can verify device details, such as manufacturer information and classification, through this database, which helps streamline monitoring and recall processes if needed.

MedCom’s devices are classified as Class I or Class II under regulatory frameworks. This classification determines the level of oversight required: Class I devices generally pose the lowest risk and may require general controls, while Class II devices, which involve moderate risk (such as software for radiation therapy planning), typically require premarket notifications (510(k)) to demonstrate substantial equivalence to a predicate device. The classification ensures that the regulatory burden aligns with the potential risk to patients, balancing safety with innovation.